Welcome to our dedicated page for Olema Pharmaceuticals SEC filings (Ticker: OLMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Olema Pharmaceuticals, Inc. filings document the regulatory record of a clinical-stage oncology company with common stock listed on the Nasdaq Global Select Market under OLMA. The company’s disclosures cover its targeted-therapy pipeline, including palazestrant and OP-3136, as well as financial results, liquidity updates, capital-structure matters, and Regulation FD investor materials.
Olema’s SEC filings also record material agreements, including lease arrangements, and governance matters such as board appointments, officer departures, indemnification agreements, compensation arrangements, and equity awards. Proxy materials address director elections, executive compensation, equity incentive plans, pay-versus-performance disclosure, and shareholder voting matters.
Shane W. Kovacs reported proposed sales of Common Stock on Form 144 handled through Fidelity Brokerage Services LLC. The filing lists recent dispositions in the past three months: 01/15/2026 sale of $2,873,214.99 (100,000 shares), 02/23/2026 sale of $723,007.46 (30,000 shares), 02/24/2026 sale of $500,002.00 (20,000 shares), 02/12/2026 sale of $238,498.19 (10,000 shares) and an earlier 01/13/2026 entry of $107,069.20 (3,822 shares). The filing identifies the broker as Fidelity Brokerage Services LLC.
Olami Medical submitted a Form 144 notice reporting a proposed resale of 20,000 common shares on 02/24/2026. The filing lists the securities as restricted stock that vested on 06/15/2020 and shows multiple recent sales by Shane W. Kovacs totaling 143,822 shares across dates in 01/2026 and 02/2026.
OLMA Form 144 filing reports proposed and recent sales of common stock by an insider. The excerpt shows Shane W. Kovacs sold 3,822 shares on 01/13/2026, 100,000 shares on 01/15/2026, and 10,000 shares on 02/12/2026, with dollar amounts listed for each sale. The filing also lists 10,000 shares associated with Fidelity Brokerage Services LLC dated 02/23/2026.
OLMA filer submitted a Form 144 reporting a proposed sale of 20,000 common shares by Fidelity Brokerage Services LLC. The filing also discloses recent reported sales by Shane W. Kovacs, including a sale of 100,000 shares for $2,873,214.99 on 01/15/2026 and 10,000 shares for $238,498.19 on 02/12/2026.
Olema Pharmaceuticals reported that its VP of Finance and Controller, Sasha Lu Austin, acquired equity awards on February 2, 2026. The awards include a stock option for 29,250 shares at an exercise price of $0.00 and a grant of 11,700 shares of common stock, both recorded as awards rather than open-market purchases.
According to the vesting terms, 25% of the option shares vest on February 2, 2027, with the remaining shares vesting in equal monthly installments over the following three years, subject to continued service. All holdings are reported as direct ownership.
Olema Pharmaceuticals, Inc. executive Austin Sasha Lu, the VP of Finance and Controller, filed an initial ownership report detailing equity holdings in the company. As of January 30, 2026, Lu directly holds 4,488 shares of common stock and multiple stock option awards. These stock options are structured to vest monthly over multi‑year periods, with several grants featuring 25% vesting on specified initial dates and the remaining 75% vesting in equal monthly installments, all contingent on continued service with Olema.
Janus Henderson Group plc filed an amended Schedule 13G reporting beneficial ownership of 6,710,194 shares of Olema Pharmaceuticals, Inc. common stock, representing 8.4% of the class as of 12/31/2025.
The stake is held through various Janus Henderson asset management subsidiaries in discretionary managed portfolios. These asset managers share voting and dispositive power over the shares, while the underlying managed portfolios receive all dividends and sale proceeds. No individual managed portfolio owns more than five percent of Olema’s common stock. Janus Henderson certifies the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Olema.
Bain Capital Life Sciences Opportunities IV, L.P. has reported a passive ownership stake in Olema Pharmaceuticals, Inc. common stock on a Schedule 13G/A. As of December 31, 2025, it is deemed to beneficially own 8,508,641 shares, representing 9.99% of the outstanding common stock.
The position consists of 1,989,775 common shares and pre-funded warrants initially exercisable for up to 8,013,216 additional shares, but a 9.99% “Beneficial Ownership Blocker” caps how many warrant shares are counted for regulatory purposes. The filing states the securities were not acquired to change or influence control of Olema.
Olema Pharmaceuticals, Inc. is the subject of an amended Schedule 13G filing in which Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report that they now beneficially own 0 shares of Olema common stock, representing 0.00% of the class.
The filing confirms they have no sole or shared voting or dispositive power over Olema shares and that they own 5% or less of the outstanding common stock. Ownership percentages are calculated using 78,652,730 Olema common shares outstanding as of November 19, 2025, as disclosed in the company’s prospectus.
Olema Oncology insider plans additional stock sale under Rule 144. A holder has filed to sell 10,000 shares of Olema common stock through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $238,498.19, targeting an approximate sale date of 02/12/2026.
The 10,000 shares were acquired on 06/15/2020 via restricted stock vesting from the issuer as compensation. In the past three months, the same seller disposed of 3,822 common shares for gross proceeds of $107,069.20 and 100,000 common shares for gross proceeds of $2,873,214.99.